MYGN – Myriad Genetics, Inc.
Myriad Genetics, Inc.MYGN
$8.09Name : Myriad Genetics, Inc.
Sector : Healthcare
Industry: Diagnostics & Research
Mark. Cap: $738,690,688.00
EPSttm : -1.41
Myriad Genetics, Inc.
$8.09
4.26%$0.36Float Short %
5.83
Margin Of Safety %
Put/Call OI Ratio
0.15
EPS Next Q Diff
0.11
EPS Last/This Y
1.48
EPS This/Next Y
0.2
Price
8.44
Target Price
15.72
Analyst Recom
2.65
Performance Q
-40.91
Relative Volume
1.39
Beta
1.89
Ticker: MYGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-11 | MYGN | 10.21 | 0.11 | 1.00 | 2095 |
| 2025-03-12 | MYGN | 10.42 | 0.11 | 0.00 | 2095 |
| 2025-03-13 | MYGN | 9.7 | 0.11 | 5.00 | 2097 |
| 2025-03-14 | MYGN | 10.09 | 0.11 | 999.99 | 2105 |
| 2025-03-17 | MYGN | 10.13 | 0.11 | 0.00 | 2105 |
| 2025-03-18 | MYGN | 9.91 | 0.10 | 0.00 | 2379 |
| 2025-03-19 | MYGN | 9.94 | 0.08 | 0.00 | 2905 |
| 2025-03-20 | MYGN | 9.91 | 0.08 | 1.45 | 2917 |
| 2025-03-21 | MYGN | 10.02 | 0.08 | 1.45 | 2917 |
| 2025-03-24 | MYGN | 9.98 | 0.18 | 0.00 | 1436 |
| 2025-03-25 | MYGN | 9.74 | 0.17 | 1.00 | 1531 |
| 2025-03-26 | MYGN | 9.2 | 0.17 | 999.99 | 1533 |
| 2025-03-27 | MYGN | 9.21 | 0.17 | 0.33 | 1534 |
| 2025-03-28 | MYGN | 8.88 | 0.17 | 999.99 | 1531 |
| 2025-03-31 | MYGN | 8.87 | 0.17 | 1.00 | 1536 |
| 2025-04-01 | MYGN | 8.85 | 0.17 | 1.00 | 1536 |
| 2025-04-02 | MYGN | 8.79 | 0.17 | 1.00 | 1536 |
| 2025-04-03 | MYGN | 8.4 | 0.16 | 0.00 | 1535 |
| 2025-04-04 | MYGN | 8.12 | 0.16 | 18.00 | 1535 |
| 2025-04-07 | MYGN | 8.06 | 0.15 | 5.00 | 1518 |
| 2025-04-08 | MYGN | 7.73 | 0.15 | 0.00 | 1521 |
| 2025-04-09 | MYGN | 8.44 | 0.15 | 0.00 | 1531 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-11 | MYGN | 10.27 | -430.9 | 131.0 | 0.06 |
| 2025-03-12 | MYGN | 10.41 | -450.1 | 130.5 | 0.06 |
| 2025-03-13 | MYGN | 9.70 | -450.1 | 129.7 | 0.06 |
| 2025-03-14 | MYGN | 10.07 | -453.5 | 130.7 | 0.06 |
| 2025-03-17 | MYGN | 10.12 | -453.5 | 130.4 | 0.06 |
| 2025-03-18 | MYGN | 9.90 | -453.5 | 130.2 | 0.06 |
| 2025-03-19 | MYGN | 9.93 | -453.5 | 130.4 | 0.06 |
| 2025-03-20 | MYGN | 9.91 | -471.6 | 130.4 | 0.07 |
| 2025-03-21 | MYGN | 10.02 | -471.6 | 130.5 | 0.07 |
| 2025-03-24 | MYGN | 9.98 | -471.6 | 130.3 | 0.07 |
| 2025-03-25 | MYGN | 9.73 | -471.6 | 130.1 | 0.07 |
| 2025-03-26 | MYGN | 9.21 | -471.6 | 129.9 | 0.07 |
| 2025-03-27 | MYGN | 9.22 | -471.6 | 130.4 | 0.07 |
| 2025-03-28 | MYGN | 8.88 | -471.6 | 130.0 | 0.07 |
| 2025-03-31 | MYGN | 8.87 | -471.6 | 130.4 | 0.07 |
| 2025-04-01 | MYGN | 8.84 | -471.6 | 130.4 | 0.07 |
| 2025-04-02 | MYGN | 8.80 | -473.5 | 130.3 | 0.07 |
| 2025-04-03 | MYGN | 8.41 | -473.5 | 130.0 | 0.07 |
| 2025-04-04 | MYGN | 8.12 | -473.5 | 130.1 | 0.07 |
| 2025-04-07 | MYGN | 8.07 | -473.5 | 130.3 | 0.07 |
| 2025-04-08 | MYGN | 7.73 | -473.5 | 130.0 | 0.07 |
| 2025-04-09 | MYGN | 8.44 | -473.5 | 131.2 | 0.07 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-11 | MYGN | -0.90 | 1.67 | 6.19 |
| 2025-03-12 | MYGN | -0.90 | 1.67 | 5.59 |
| 2025-03-13 | MYGN | -0.42 | 1.67 | 5.59 |
| 2025-03-14 | MYGN | -0.42 | 1.67 | 5.59 |
| 2025-03-17 | MYGN | -0.42 | 1.67 | 5.59 |
| 2025-03-18 | MYGN | -0.42 | 1.67 | 5.59 |
| 2025-03-19 | MYGN | -0.42 | 1.67 | 5.59 |
| 2025-03-20 | MYGN | -0.42 | 1.67 | 5.59 |
| 2025-03-21 | MYGN | -0.42 | 1.67 | 5.59 |
| 2025-03-24 | MYGN | -0.42 | 1.67 | 5.63 |
| 2025-03-25 | MYGN | -0.36 | 1.67 | 5.63 |
| 2025-03-26 | MYGN | -0.36 | 1.67 | 5.84 |
| 2025-03-27 | MYGN | -0.36 | 1.67 | 5.84 |
| 2025-03-28 | MYGN | -0.36 | 1.67 | 5.84 |
| 2025-03-31 | MYGN | -0.36 | 1.64 | 5.83 |
| 2025-04-01 | MYGN | -0.37 | 1.64 | 5.83 |
| 2025-04-02 | MYGN | -0.37 | 1.64 | 5.83 |
| 2025-04-03 | MYGN | -0.37 | 1.64 | 5.83 |
| 2025-04-04 | MYGN | -0.37 | 1.64 | 5.83 |
| 2025-04-07 | MYGN | -0.37 | 1.66 | 5.83 |
| 2025-04-08 | MYGN | -0.37 | 1.66 | 5.83 |
| 2025-04-09 | MYGN | -0.37 | 1.66 | 5.83 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.09
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
0.02
Insider Transactions
-0.37
Institutional Transactions
1.66
Beta
1.89
Average Sales Estimate Current Quarter
201
Average Sales Estimate Next Quarter
212
Fair Value
Quality Score
49
Growth Score
43
Sentiment Score
29
Actual DrawDown %
77.2
Max Drawdown 5-Year %
-78.9
Target Price
15.72
P/E
Forward P/E
33.67
PEG
P/S
0.92
P/B
1.1
P/Free Cash Flow
EPS
-1.4
Average EPS Est. Cur. Y
0.07
EPS Next Y. (Est.)
0.27
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-15.2
Relative Volume
1.39
Return on Equity vs Sector %
-37.8
Return on Equity vs Industry %
-28.9
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
131.2
Myriad Genetics, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2700
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
stock quote shares MYGN – Myriad Genetics, Inc. Stock Price stock today
news today MYGN – Myriad Genetics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MYGN – Myriad Genetics, Inc. yahoo finance google finance
stock history MYGN – Myriad Genetics, Inc. invest stock market
stock prices MYGN premarket after hours
ticker MYGN fair value insiders trading